INS and diabetic kidney disease: The predicted bioactivity of these compounds, as determined by PASS Online, includes glucan endo-1,6-beta-glucosidase inhibitor, α-amylase inhibitor, beta-amylase inhibitor, antidiabetic symptomatic, antidiabetic, diabetic neuropathy treatment, diabetic retinopathy treatment, diabetic nephropathy treatment, and insulin promoter effects.